Trametinib
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Trametinib: From BRAF V600-Mutant Cutaneous Melanoma to Non-Cutaneous Melanoma
One-Sentence Summary
Trametinib is a MEK1/2 inhibitor established (in combination with the BRAF inhibitor dabrafenib) for the treatment of BRAF V600 mutation-positive cutaneous melanoma. The TxGNN model’s evidence pack points most credibly toward Non-Cutaneous Melanoma (melanoma arising outside typical skin sites, e.g., mucosal, ocular, acral) as a mechanistically plausible extension of the same BRAF/MEK-driven biology, supported by 50 clinical trials currently on record, though these trials largely enrolled classic cutaneous BRAF-mutant melanoma populations rather than non-cutaneous subtypes specifically. Note: the model’s single highest-scoring prediction (choroideremia, an inherited retinal disorder) is explicitly flagged within the evidence pack itself as a likely knowledge-graph embedding artifact with no mechanistic basis, and is not used as the lead candidate in this report.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in the evidence pack (no EU marketing authorization on file); trial evidence in the pack indicates established use as combination therapy for BRAF V600 mutation-positive cutaneous melanoma |
| Predicted New Indication | Non-Cutaneous Melanoma |
| TxGNN Prediction Score | 99.30% |
| Evidence Level | L2 |
| EU Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism-of-action documentation is not available in this evidence pack (flagged as a High-severity data gap). Based on information embedded in the clinical trial records themselves, trametinib is repeatedly described as “a reversible and highly selective allosteric inhibitor of MEK1 and MEK2,” used in combination with the BRAF inhibitor dabrafenib to block the MAPK signalling pathway that is constitutively activated by BRAF V600 mutations.
Non-cutaneous melanoma — arising in mucosal, ocular, acral, or other non-skin sites — is histogenetically the same malignancy (malignant transformation of melanocytes) as cutaneous melanoma, and a meaningful proportion of cases, particularly mucosal and acral subtypes, carry the same BRAF V600 mutations or BRAF fusion events that activate the MAPK pathway. The rationale in this evidence pack therefore frames the prediction not as a mechanistic leap, but as an anatomical-site extension of an already-validated molecular target within the same tumor lineage.
Because trametinib/dabrafenib efficacy is driven by BRAF mutation status rather than anatomic origin, the mechanism is plausible across melanoma subtypes; however, most of the 50 supporting trials in this evidence pack enrolled predominantly cutaneous melanoma patients, so trial-level confirmation is indirect rather than subtype-specific. For context, a closely related sub-indication in this same evidence pack — mucosal melanoma — carries direct molecular literature (e.g., BRAF fusion genes shown to activate MAPK signalling and confer MEK-inhibitor sensitivity in mucosal melanoma) and a dedicated retrospective cohort study (NCT06337617) with separate mucosal and non-mucosal analysis arms, reinforcing that the underlying biological hypothesis is credible even though it is not yet confirmed by a prospective trial dedicated to non-cutaneous melanoma as a whole.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01597908 | Phase 3 | Completed | 704 | COMBI-v: randomized trial showing dabrafenib+trametinib combination outperformed BRAF-inhibitor monotherapy (vemurafenib) in BRAF V600E/K-mutant unresectable/metastatic melanoma |
| NCT01245062 | Phase 3 | Completed | 322 | METRIC: trametinib monotherapy vs chemotherapy in BRAF V600E/K-mutant advanced melanoma; foundational trial for MEK-inhibitor approval |
| NCT02967692 | Phase 3 | Terminated | 568 | Randomized triplet trial adding anti-PD-1 (PDR001) to dabrafenib+trametinib vs placebo in BRAF V600-mutant melanoma; terminated early |
| NCT01072175 | Phase 2 | Completed | 430 | Dose-escalation study establishing PK/PD and clinical activity of the dabrafenib+trametinib combination, forming the basis for later pivotal trials |
| NCT02645149 | Phase 2 | Completed | 216 | Molecular-profiling-matched targeted therapy in unresectable/metastatic melanoma progressing on immunotherapy |
| NCT03944356 | N/A | Completed | 232 | Non-interventional real-world observatory study of adjuvant dabrafenib+trametinib use in melanoma clinical practice |
| NCT02130466 | Phase 1/2 | Completed | 184 | Pembrolizumab + dabrafenib + trametinib triplet dose-finding and efficacy study in advanced melanoma (KEYNOTE-022) |
| NCT02039947 | Phase 2 | Completed | 127 | Dabrafenib+trametinib across BRAF V600 E/D/K/R subtypes in melanoma with brain metastases, symptomatic and asymptomatic cohorts |
| NCT02083354 | Phase 2 | Completed | 77 | Objective response rate of dabrafenib+trametinib in BRAF V600-mutant acral lentiginous or cutaneous melanoma |
| NCT01619774 | Phase 2 | Completed | 28 | Dabrafenib+trametinib in melanoma refractory/resistant to prior BRAF-inhibitor monotherapy, including brain metastases |
40 additional trials are on record for this indication, spanning Phase 1–3 and covering combination regimens, PK/ADME, biomarker-driven, and real-world settings; the ten above represent the largest and most methodologically robust studies.
Literature Evidence
Currently no related literature available for this specific indication (Non-Cutaneous Melanoma) in the evidence pack.
Note: a closely related, more anatomically specific candidate in the same evidence pack — mucosal melanoma — does have supporting literature, including mechanistic studies on oncogenic BRAF fusions activating the MAPK pathway (PMID 28092667) and preclinical canine models of MEK inhibition with trametinib (GSK1120212) in mucosal melanoma (PMID 27463366, PMID 32943547).
EU Market Information
No EU marketing authorization is on file for trametinib in this evidence pack (0 authorizations, market status: Not marketed). No product/authorization-level detail is therefore available to tabulate.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (MEK1/MEK2 inhibitor), based on descriptions within the clinical trial records in this evidence pack |
| Myelosuppression Risk | Please refer to the SmPC warnings and precautions |
| Emetogenicity Classification | Please refer to the SmPC warnings and precautions |
| Monitoring Items | Please refer to the SmPC warnings and precautions |
| Handling Protection | Please refer to the SmPC warnings and precautions |
Safety Considerations
Please refer to the SmPC for safety information. Key warnings, contraindications, and drug-drug interaction data were not available in this evidence pack (flagged as a Blocking-severity data gap, pending TFDA/EU label retrieval).
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The mechanistic rationale is strong — BRAF/MEK pathway activation is shared across anatomic melanoma subtypes — and is backed by an extensive body of Phase 2/3 clinical evidence (L2), including large completed pivotal trials (COMBI-v, METRIC) for BRAF-mutant melanoma generally. However, these trials predominantly enrolled cutaneous melanoma patients, direct literature support for the “non-cutaneous melanoma” category as a whole is absent, and critical safety/regulatory data for this drug are currently missing.
To proceed, the following is needed:
- TFDA/EU product label (SmPC) retrieval to resolve the Blocking-severity safety data gap before any S1 safety evaluation can proceed
- Confirmed mechanism-of-action documentation from DrugBank to formally close the MOA data gap
- Subtype-specific evidence (e.g., BRAF mutation prevalence and treatment outcomes in mucosal, ocular, and acral melanoma populations) to substantiate the “non-cutaneous” grouping beyond mechanistic extrapolation
- Confirmation of current EU marketing authorization status, since this evidence pack records 0 licenses despite trametinib being an established combination therapy in melanoma
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.